Abstract:Objective: With the proposal of penumbra theory and development of intra-arterial thrombolysis (such as urokinase), the outcome of ischemic cerebrovascular disease is greatly improved. However, the incidence of hemorrhagic transformation (HT) increased concomitantly, and some studies showed a close relationship between blood pressure and HT. The mechanisms of blood pressure and urokinase effect on the incidence of HT are not clear. In this study, we investigated the effects of the different levels of blood pressure and urokinase on the ischemic lesions, the incidence of HT and the expression of matrix metalloproteinase 9 (MMP-9) in the rat ischemia-reperfusion models. Methods: Temporary focal ischemia was induced in male Sprague-Dawley rats using the intraluminal vascular occlusion method. The animals were assigned into four groups (n=11 in each group): low blood pressure group (LP), normal blood pressure group (NP), high blood pressure group (HP) and urokinase/high blood pressure group (UKHP). Adnephrin was applied to enhance the mean arterial blood pressure (MABP) at the beginning of reperfusion. MABP was maintained 20 mmHg higher than the baseline for 1 hour. Sodium nitroprusside was used to decrease MABP by 20 mmHg lower than the baseline for 1 hour. Both urokinase and adnephrin were used concomitantly in the UKHP group. Neurological deficit scores were evaluated at 2 hours (R2h) and 24 hours (R24h) after reperfusion. All rats were decapitated, their brains were sliced into 15-mu m-thick slices, and the infarct volume and the visible HT were analysed. Three rats in each group were taken for immunohistochemistry and pathological analysis. Results: There was no significant difference in MABP among the groups at the baseline time points (p>0.05), but blood pressure are definitely increased and decreased in the HP, UKHP, and LP groups. Neurological deficit scores showed no significant difference at R2h among the groups (p=0.443). However, neurological deficit scores showed significant differences at R24h among the groups, the neurological deficits scores of rats in the LP group are significantly higher than that in the other groups. Compared with that of 2 hours after reperfusion, neurological deficit scores deteriorated in the LP group (p=0.047) but was improved in the NP, HP and UKHP groups (p=0.076, 0.002, 0.017, respectively) at 24 hours after reperfusion. The infarct volume in the HP group was apparently smaller than that in the LP group (p=0.006). There was indeed a tendency that HT occurred more frequently in the UKHP group (42.8%) than in the HP (25%) and LP (28.5%) groups. MMP-9 expression showed significant increase around the ischemic lesion areas of the UKHP group and significant decrease in the cortical areas of the LP and HP groups but no significant difference in the basal ganglia of rats of all groups. Conclusion: Mild elevation of blood pressure during reperfusion is supposed to improve neurological outcomes in rats following ischemia/reperfusion. The incidence of HT tended to increase with the elevation of blood pressure and the administration of urokinase. Immunohistochemitry analysis indicated that incidence of HT may correlate with excessive expression of MMP-9. [Neurol Res 2009; 31: 204-208]

Human Urinary Kallidinogenase Promotes Angiogenesis and Cerebral Perfusion in Experimental Stroke.

Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-|[kappa]|B

Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke.

Human Urinary Kallidinogenase Improves Outcome of Stroke Patients by Shortening Mean Transit Time of Perfusion Magnetic Resonance Imaging.

Annexin A2 Promotes Angiogenesis after Ischemic Stroke Via Annexin A2 Receptor – AKT/ERK Pathways

The effectiveness and safety of human urinary kallidinogenase in acute ischemic stroke patients undergoing endovascular therapy

Human Urinary Kallidinogenase in Treating Acute Ischemic Stroke Patients: Analyses of Pooled Data from a Randomized Double-Blind Placebo-Controlled Phase IIb and Phase III Clinical Trial

Human urinary kallidinogenase may improve the prognosis of acute stroke patients with early neurological deterioration

Human Urinary Kallidinogenase Improves Vascular Endothelial Injury by Activating the Nrf2/HO-1 Signaling Pathway

Protective effects of human urinary kallidinogenase against corticospinal tract damage in acute ischemic stroke patients

A Multicenter, Randomized,double-Blinded and Placebo-Controlled Study of Acute Brain Infarction Treated by Humanurinary Kallidinogenase

Human Urinary Kallidinogenase Promotes Good Recovery in Ischemic Stroke Patients with Level 3 Hypertension.

The Combination of Human Urinary Kallidinogenase and Mild Hypothermia Protects Adult Rats Against Hypoxic-Ischemic Encephalopathy-Induced Injury by Promoting Angiogenesis and Regeneration.

Human Urinary Kallidinogenase Pretreatment Inhibits Myocardial Inflammation and Apoptosis after Coronary Microembolization by Activating PI3K/Akt/FoxO1 Axis

Therapeutic Values of Human Urinary Kallidinogenase on Cerebrovascular Diseases

Human urinary kallidinogenase in acute ischemic stroke: A single-arm, multicenter, phase IV study (RESK study)

The effects of blood pressure and urokinase on brain injuries after experimental cerebral infarction in rats.

Multi-modality CT study about the impact of human urinary kallidinogenase (HUK) on collateral circulation and blood perfusion in patients with acute cerebral ischemia (ACI)

Human Urinary Kallidinogenase or Edaravone Combined with Butylphthalide in the Treatment of Acute Ischemic Stroke

Exogenous kallikrein enhances neurogenesis and angiogenesis in the subventricular zone and the peri-infarction region and improves neurological function after focal cortical infarction in hypertensive rats.

The Effect of Human Urinary Kallidinogenase on the Cerebrovascular Reserve Capacity in Cerebral Ischemic Rabbits